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Abstract
Guidelines on lipid-lowering treatment for prevention of CVD (cardiovascular diseases) 
are issued by the American College of Cardiology/American Heart Association (ACC/AHA) 
and the European Society of Cardiology (ESC).1,2,3 The recommendations for lipid-lowering 
treatment initiation from both guidelines are based on evidence from randomized clinical trials 
demonstrating the effi cacy of statins for primary and secondary prevention of CVD. 
However, there were discrepancies existed between the current CVD prevention guidelines on 
both sides of the Atlantic continent and available trial evidence. Yet, for 1 of 5 adults aged 45 to 
75 years, both guidelines and presence of RCT evidence support statin treatment for primary 
prevention of CVD.4Large-scale evidence from randomized trials shows that statin therapy 
reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, 
and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction 
in LDL cholesterol during each year (after the fi rst) that it continues to be taken. The absolute 
benefi ts of statin therapy depend on an individual’s absolute risk of occlusive vascular events 
and the absolute reduction in LCL cholesterol that is achieved either in primary prevention and 
secondary prevention settings.5
Statin therapy has been shown to reduce vascular disease risk during each year it continues 
to be taken, so larger absolute benefi ts would accrue with more prolonged therapy, and these 
benefi ts persist long term. The only serious adverse events that have been shown to be caused 
by lomg-term statin therapy; ie, adverse effects of the statin – are myopathy and new-onset 
diabetes mellitus.5
Because improved patients outcomes have been demonstrated for these individuals, it should 
be an imperative to ensure that they are identifi ed and are offered optimal evidence-based 
treatment to reduce the burden of CVD. 
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